Clinical trials: Psoriasis Chronic
Moderate to Severe Plaque-type Psoriasis
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- FEATURE (NCT01555125)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
- Trial name
- PsOsim (NCT02489227)
- Testing
- CHS-1420, Adalimumab
- Where
- 99 sites in United States, Bulgaria and 14 more
- Volunteers
- 545 people
- Sponsor
- Coherus Oncology, Inc.
Psoriasis
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support…
- Trial name
- NCT02694523
- Testing
- risankizumab, adalimumab
- Volunteers
- 684 people
- Sponsor
- AbbVie
Healthy Volunteers, Mild to Moderate Psoriasis
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of…
- Trial name
- NCT05965089
- Testing
- AX-202
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Arxx Therapeutics
Psoriasis
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis.
- Trial name
- NCT01519089
- Testing
- CP-690,550, CP-690, 550
- Where
- 16 sites in Japan
- Volunteers
- 95 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling
The purpose of this study is to collect skin biopsies and non-invasive microneedle device samples from participants with mild chronic plaque psoriasis vulgaris to use for transcriptomics profiling for further investigation.
- Trial name
- NCT03795402
- Testing
- Microneedle Device
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
Psoriasis, the most prevalent autoimmune disease in the U.S., manifests with plaque type psoriasis vulgaris with lesions localized to the scalp, postauricular region, face, diaper area, elbows, and knees.
- Trial name
- NCT03848806
- Testing
- HAT1, Calcipotriol
- Volunteers
- 174 people
- Sponsor
- Haus Bioceuticals
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE RADIANT (NCT03536884)
- Testing
- Bimekizumab, Secukinumab
- Where
- 77 sites in United States, Australia and 9 more
- Volunteers
- 743 people
- Sponsor
- UCB Biopharma SRL
Chronic Plaque Psoriasis
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult…
- Trial name
- DERMIS-1 (NCT04211363)
- Testing
- Roflumilast 0.3% cream, Vehicle Cream
- Where
- 40 sites in United States, Canada
- Volunteers
- 439 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- Opportuniti (NCT04785326)
- Testing
- DMB-3115, Stelara
- Where
- 2 sites in United States
- Volunteers
- 598 people
- Sponsor
- Dong-A ST Co., Ltd.
Moderate to Severe Chronic Plaque Psoriasis
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
This was a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for…
- Trial name
- NCT05388916
- Testing
- Cosentyx
- Where
- 7 sites in China
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
- Trial name
- NCT03897075
- Testing
- Tildrakizumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 99 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).
- Trial name
- NCT02134210
- Testing
- Etanercept, CHS-0214
- Where
- 100 sites in United States, Australia and 5 more
- Volunteers
- 521 people
- Sponsor
- Coherus Oncology, Inc.
Chronic Plaque-type Psoriasis
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
The aim of this study was to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic…
- Trial name
- ARROW (NCT03553823)
- Testing
- Skin biopsies
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque-Type Psoriasis
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of…
- Trial name
- NCT01640951
- Testing
- AIN457 150 mg, AIN457 300 mg
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
The objective of this Phase 2 trial is to determine the efficacy and safety of LYC-30937-EC in patients with moderate plaque-type psoriasis.
- Trial name
- NCT02872285
- Testing
- Drug: LYC-30937-EC
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lycera Corp.
Psoriasis Chronic
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs
The aim of this post-marketing observational study (PMOS) was to obtain further data on long-term safety, efficacy, and quality of life outcomes for adalimumab in routine clinical use in participants with moderate to severe…
- Trial name
- QUALITY (NCT01084668)
- Where
- 9 sites in Austria
- Volunteers
- 46 people
- Sponsor
- Abbott
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- ERASURE (NCT01365455)
- Testing
- secukinumab 150 mg
- Where
- 88 sites in United States, Argentina and 10 more
- Volunteers
- 738 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
The general aim of the trial is to determine the safety, tolerability and pharmacologic profile of single escalating doses of AbGn-168 administered subcutaneously or intravenously to patients with chronic plaque psoriasis
- Trial name
- NCT00848055
- Testing
- AbGn168 intravenous infusion, AbGn168 subcutaneous injection
- Where
- 7 sites in United States, Germany
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Chronic Plaque-type Psoriasis
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body…
- Trial name
- NCT00941031
- Testing
- AIN457, AIN457A
- Where
- 62 sites in United States, France and 5 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals